Bascom Cleft Lift for Primary Wound Healing in Complex and Recurrent Sacrococcygeal Pilonidal Sinus Disease
Launched by ALBERT SCHWEITZER ZIEKENHUIS, NETHERLANDS · Nov 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treating complex or recurring pilonidal sinus disease, which is a painful condition that can occur near the tailbone. The researchers want to find out if a specific surgical method called the cleft lift, when combined with a best practice care plan, helps patients heal faster and return to their normal activities sooner than the usual treatment that uses traditional excision techniques.
To participate in this study, you need to be 16 years or older and have been experiencing symptoms of complex or recurring pilonidal sinus disease. You must also be planning to have surgery and be able to give your consent. This trial is currently recruiting participants, and it welcomes individuals of any gender. If you join, you can expect to receive care based on the new pathway, which aims to improve your healing process. It’s important to note that pregnant individuals or those who cannot understand Dutch sufficiently will not be able to take part in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 16 years of age and older
- • Symptomatic complex or recurrent pilonidal sinus disease
- • Planned for surgical treatment
- • Signed informed consent
- Exclusion Criteria:
- • Pregnant
- • Insufficient understanding of the Dutch language or otherwise unable to give consent
About Albert Schweitzer Ziekenhuis, Netherlands
Albert Schweitzer Ziekenhuis, located in the Netherlands, is a leading healthcare institution dedicated to providing high-quality medical services and advancing clinical research. With a strong emphasis on patient-centered care, the hospital integrates innovative practices and cutting-edge technology in its clinical trials. The institution fosters collaboration among multidisciplinary teams, aiming to enhance treatment outcomes and contribute significantly to medical knowledge. Committed to ethical standards and regulatory compliance, Albert Schweitzer Ziekenhuis plays a pivotal role in developing new therapies and improving healthcare delivery within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dordrecht, , Netherlands
Patients applied
Trial Officials
Robert Smeenk, MD, PhD
Principal Investigator
Albert Schweitzer Ziekenhuis, Netherlands
Boudewijn Toorenvliet, MD, PhD
Principal Investigator
Ikazia ziekenhuis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported